Gilead Sciences, Inc. - Product Pipeline Review - 2016

  • ID: 3665210
  • Company Profile
  • 138 pages
  • Global Markets Direct
  • Gilead Sciences Inc
1 of 4
Gilead Sciences, Inc. - Product Pipeline Review - 2016

Summary

‘Gilead Sciences, Inc. - Product Pipeline Review - 2016’, provides an overview of the Gilead Sciences, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Gilead Sciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Gilead Sciences, Inc.
- The report provides overview of Gilead Sciences, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Gilead Sciences, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Gilead Sciences, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Gilead Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Gilead Sciences, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gilead Sciences, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Gilead Sciences, Inc. Snapshot

Gilead Sciences, Inc. Overview

Key Information

Key Facts

Gilead Sciences, Inc. - Research and Development Overview

Key Therapeutic Areas

Gilead Sciences, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Gilead Sciences, Inc. - Pipeline Products Glance

Gilead Sciences, Inc. - Late Stage Pipeline Products

Gilead Sciences, Inc. - Clinical Stage Pipeline Products

Gilead Sciences, Inc. - Early Stage Pipeline Products

Gilead Sciences, Inc. - Drug Profiles

(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)

(emtricitabine + tenofovir alafenamide fumarate)

(sofosbuvir + velpatasvir)

tenofovir alafenamide

(cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide fumarate)

(emtricitabine + GS-9883 + tenofovir alafenamide)

(GS-9857 + sofosbuvir + velpatasvir)

ambrisentan

eleclazine

GS-5745

idelalisib

momelotinib dihydrochloride

acalisib

entospletinib

GS-4774

presatovir

ranolazine ER

regadenoson

selonsertib

selonsertib + simtuzumab

simtuzumab

vesatolimod

GS-5829

GS-5734

GS-9674

GS-9876

ONO-4059

GS-459679

GS-548202

GS-5759

GS-607601

GS-8374

GS-967

GS-986

Monoclonal Antibodies 1 for Oncology

Monoclonal Antibody for HIV / AIDS

Monoclonal Antibody to Target HIV-Envelope and CD3 for HIV

Px-103

Small Molecule to Inhibit Histone Deacetylation for Oncology

Small Molecule to Inhibit Histone Methyltransferase for Oncology

GS-563253

GS-599220

Small Molecule for RSV

Small Molecule to Inhibit NS4B Protein for HCV

Small Molecules for Hepatitis C Infection

Small Molecules to Inhibit NS3 Protease for Hepatitis C

Small Molecules to Inhibit NS5B for Hepatitis C

Gilead Sciences, Inc. - Pipeline Analysis

Gilead Sciences, Inc. - Pipeline Products by Target

Gilead Sciences, Inc. - Pipeline Products by Route of Administration

Gilead Sciences, Inc. - Pipeline Products by Molecule Type

Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action

Gilead Sciences, Inc. - Recent Pipeline Updates

Gilead Sciences, Inc. - Dormant Projects

Gilead Sciences, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Gilead Sciences, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Gilead Sciences, Inc., Key Information

Gilead Sciences, Inc., Key Facts

Gilead Sciences, Inc. - Pipeline by Indication, 2016

Gilead Sciences, Inc. - Pipeline by Stage of Development, 2016

Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2016

Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2016

Gilead Sciences, Inc. - Partnered Products in Pipeline, 2016

Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2016

Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Gilead Sciences, Inc. - Pre-Registration, 2016

Gilead Sciences, Inc. - Phase III, 2016

Gilead Sciences, Inc. - Phase II, 2016

Gilead Sciences, Inc. - Phase I, 2016

Gilead Sciences, Inc. - Preclinical, 2016

Gilead Sciences, Inc. - Discovery, 2016

Gilead Sciences, Inc. - Pipeline by Target, 2016

Gilead Sciences, Inc. - Pipeline by Route of Administration, 2016

Gilead Sciences, Inc. - Pipeline by Molecule Type, 2016

Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2016

Gilead Sciences, Inc. - Recent Pipeline Updates, 2016

Gilead Sciences, Inc. - Dormant Developmental Projects,2016

Gilead Sciences, Inc. - Discontinued Pipeline Products, 2016

Gilead Sciences, Inc., Other Locations

Gilead Sciences, Inc., Subsidiaries

List of Figures

Gilead Sciences, Inc. - Pipeline by Top 10 Indication, 2016

Gilead Sciences, Inc. - Pipeline by Stage of Development, 2016

Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2016

Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2016

Gilead Sciences, Inc. - Partnered Products in Pipeline, 2016

Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2016

Gilead Sciences, Inc. - Pipeline by Top 10 Target, 2016

Gilead Sciences, Inc. - Pipeline by Route of Administration, 2016

Gilead Sciences, Inc. - Pipeline by Molecule Type, 2016

Gilead Sciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll